Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease

 

Cannabinoids: Novel medicines for the treatment of Huntington’s disease

 

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and

CB(2) receptors

 

Controlled clinical trial of cannabidiol in Huntington’s disease

 

Prospects for cannabinoid therapies in basal ganglia disorders

 

Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice